Christine L. Phillips, MD

The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Rubinstein, JD; Breese, EH; Krupski, MC; O'Brien, MM; Dandoy, CE; Mizukawa, B; Khoury, R; Norris, RE; Davies, SM; Phillips, CL. Transplantation and cellular therapy. 2023.

Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation. Bender, JD; Oquendo-del Toro, H; Benoit, J; Howell, JC; Badia, P; Davies, SM; Grimley, MS; Jodele, S; Phillips, C; Burns, K; et al. Transplantation and cellular therapy. 2023; 29:130.e1-130.e8.

Tocilizumab for Treatment of Children and Young Adults With Severe Acute COVID-19: Experience at a Quaternary-care Children's Hospital. Teoh, Z; Danziger-Isakov, L; Courter, JD; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Phillips, CL; Spearman, P; Chima, RS; et al. Pediatric Infectious Disease Journal. 2023; 42:119-121.

262 High Disease Burden and Severe Neutropenia Predict HLH Toxicity in Patients with B-Acute Lymphoblastic Leukemia (B-ALL) Treated with Tisagenlecleucel in the PRWCC. McNerney, KO; Lim, SS; Miller, A; Amankwah, E; Dreyzin, A; Vatsayan, A; Hermiston, M; Baggott, C; Prabhu, S; Pacenta, HL; et al. Transplantation and cellular therapy. 2023; 29:s202-s203.

1119. Covid-19 Mab Use in High-Risk Pediatric Patients. Bahakel, H; Murphy, CR; Frenck, RW; Grimley, M; Phillips, C; Schulert, G; Spearman, P; Courter, JD; Paulsen, GC; Danziger-Isakov, LA. Open Forum Infectious Diseases. 2022; 9.

Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients. Bahakel, H; Murphy, C; Frenck, RW; Grimley, MS; Marsh, RA; Paulsen, GC; Haslam, DB; Phillips, CL; Courter, J; Spearman, P; et al. Pediatric Infectious Disease Journal. 2022; 41:985-988.

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Moskop, A; Pommert, L; Baggott, C; Prabhu, S; Pacenta, HL; Phillips, CL; Rossoff, J; Stefanski, HE; Talano, JA; Margossian, SP; et al. Blood Advances. 2022; 6:4251-4255.

Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. Schultz, LM; Baggott, C; Prabhu, S; Pacenta, HL; Phillips, CL; Rossoff, J; Stefanski, HE; Talano, JA; Moskop, A; Margossian, SP; et al. Journal of Clinical Oncology. 2022; 40:945-955.

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Fabrizio, VA; Phillips, CL; Lane, A; Baggott, C; Prabhu, S; Egeler, E; Mavroukakis, S; Pacenta, H; Rossoff, J; Stefanski, HE; et al. Blood Advances. 2022; 6:600-610.

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. Levine, JE; Grupp, SA; Pulsipher, MA; DIetz, AC; Rives, S; Myers, GD; August, KJ; Verneris, MR; Buechner, J; Laetsch, TW; et al. Journal for ImmunoTherapy of Cancer. 2021; 9.